MPTP in mice: treatment, distribution and possible source of contamination.
Mice were treated daily with [3H]MPTP (30 mg/kg, 1 uCi, s.c.) for 1, 3, and 10 days to determine the fate and localization of tritiated compounds. An untreated mouse was housed either in the same cage ("cage-mate control") or in an adjacent cage separated by mesh-wire ("near-neighbor control"). The radioactivity measured in blood, brain, liver, and remaining body of [3H]MPTP-treated mice was dependent on the total dose of the drug the animals received and did not vary with the type of tissue analyzed. Significant amounts of radioactivity were found in the tissues of the "cage-mate control" mice, but not of the "near-neighbor control" mice. The route of transmission appears to be through the urine, as the urine of [3H]MPTP-treated mice was highly radioactive after the drug injection. Only traces of radioactivity were found in their feces and there was no increase in the background radiation in the environment of the cages, indicating that the tritiated compounds were not exhaled. Proper disposal of urinary products of MPTP-treated animals is therefore necessary to reduce the risk of possible drug contamination in humans.
Crampton
J M
JM
School of Pharmacy, Parkinson's Disease Research Program, Creighton University, Omaha, NE 68178.
Runice
C E
CE
Doyle
T J
TJ
Lau
Y S
YS
Wilson
J A
JA
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D004195:Disease Models, Animal; D004781:Environmental Exposure; D005243:Feces / Q000032:analysis; D051379:Mice; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000378:metabolism; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D014556:Urine / Q000032:analysis
D011725:Pyridines; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine